Administrative Core

管理核心 导演：阿纳斯·尤尼斯，医学博士 联席主任：安德鲁·泽勒内茨，医学博士 核心摘要 淋巴瘤管理核心中MSK孢子的目的是协调 项目和核心，并监督和领导科学、行政和财政方面 淋巴瘤中的MSK孢子。《核心》将由阿纳斯·尤尼斯博士和安德鲁·泽雷内茨共同执导。 核心将协调所有孢子科学和行政会议，除了协调 项目、核心、CEP和DRP之间的沟通。行政核心还将协调 与NCI、EAB、IAB和外部协作者进行沟通，以提高水平和垂直水平 合作。管理核心将协调孢子临床试验的患者登记，并将 确保遵守保护人类主体的体制政策，并将鼓励 妇女和少数族裔参与拟议的临床试验。孢子赠款的主要优势之一是 灵活性它允许审查现有项目和核心的翻译研究生产力，并使 调整以进一步加强这一协作工作和/或及时解决新的关键问题 举止。行政核心将建立一个评价生产力和成就的程序 核心、项目、DRP和CEP提案，并将与内部和外部顾问以及 执行委员会决定停止生产率较低的活动并在#年启动新的活动 对重要的翻译研究机会作出反应。

Administrative Core Director: Anas Younes, MD Co-Director: Andrew Zelenetz, MD, PhD CORE SUMMARY The purpose of the MSK SPORE in Lymphoma Administrative Core is to coordinate the activities of the Projects and Cores and to provide oversight and leadership of the scientific, administrative, and fiscal aspects of the MSK SPORE in Lymphoma. The Core will be co-directed by Drs. Anas Younes and Andrew Zelenetz. The Core will coordinate all SPORE scientific and administrative meetings, in addition to coordinating the communications among Projects, Cores, CEP, and DRP. The administrative Core will also coordinate the communications with the NCI, EAB, IAB, and external collaborators to enhance both horizontal and vertical collaborations. The Administrative Core will coordinate enrollment of patients on SPORE clinical trials, and will ensure compliance with institutional policies to protect human subjects, and will encourage participation of women and minorities on the proposed clinical trials. One of the major advantages of the SPORE Grant is the flexibility it allows to review the translational research productivity of existing projects and cores and make adjustments to further strengthen this collaborative work and/or to address new critical questions in a timely manner. The Administrative Core will establish a process for evaluating the productivity and achievements of the Cores, Projects, DRP and CEP proposals, and will work with the Internal and External Advisors, and the Executive Committee to decide on discontinuing activities of lower productivity and initiating new activities in response to important translational research opportunities.